¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk ratio
    À§Çèºñ
  • standardized mortality ratio
    Ç¥ÁØÈ­»ç¸Áºñ
  • standardized rate ratio
    Ç¥ÁØÈ­ºñÀ²ºñ
  • stopping power ratio
    ÀúÁö´Éºñ
  • survival ratio
    »ýÁ¸ºñ
  • segregation ratio
    ºÐ¸®ºñ
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • uptake ratio
    ¼·ÃëÀ²
  • urea excretion ratio
    ¿ä¼Ò¹è¼³ºñ
  • velocity ratio
    ¼Óµµºñ
  • ventilation blood flow ratio
    ȯ±âÇ÷·ùºñÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • primary sex ratio
    ÀÏÂ÷¼ººñ
  • ratio
    ºñ, À²
  • rate ratio
    ºñÀ²ºñ
  • ratio scale
    ºñôµµ
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²
  • risk ratio
    À§Çèµµºñ
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • scatter phantom ratio
    ÆÒÅè»ê¶õºñ
  • scatter-air ratio
    »ê¶õ°ø±âºñ
  • scatter-maximum ratio
    ÃÖ´ë»ê¶õºñ
  • segregation ratio
    ºÐ¸®ºñ
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼ÒÅ©·¹¾ÆÆ¼´Ñºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • standardized mortality ratio
    Ç¥ÁØÈ­»ç¸Áºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inspiratory phase
    Èí±â»ó(ýåѨßÓ).
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • phallic stage (phase)
    ³²±Ù±â(ÑûÐÆÑ¢).
  • phase
    »ó, ±â
  • phase
    ˤȗ
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • phase I block
    Á¦1»óÂ÷´Ü.
  • phase advance
    »óÀüÁø(ßÓîñòä)
  • phase angle
    À§»ó°¢(êÈßÓÊÇ).
  • phase angle
    À§»ó °¢
  • phase artifact
    À§»ó Àΰø¹°
  • phase axis
    ˤȗ ̈
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • ratio
    ºñ(ËÓ).
  • ratio estimate
    ºñÃßÁ¤·®(ËÓÌ§ËøËâ).
  • ratio intelligence qoutient
    Áö´ÉºñÀ²Áö¼ö
  • ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • ratio of dependants
    ºÎ¾çºñ(ËÓËâËÓ).
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²(û¼ýåÎßüµÝïëÒ).
  • scatter phantom ratio
    ÆÒÅè»ê¶õºñ
  • scatter-air ratio, SAR
    »ê¶õ°ø±âºñ
  • scatter-air-ratio
    »ê¶õ°ø±âÀ²
  • scatter-maximum-ratio
    ÃÖ´ë»ê¶õºñ
  • segregation ratio
    ºÐ¸®ºñ.
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñ ºñ
  • sex ratio
    ¼ººñ.
  • signal to noise ratio (SNR)
    ½ÅÈ£ ´ë ÀâÀ½ºñ
  • specific absorption ratio, SAR
    Ư¼ºÈí¼öÀ²
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • phase variation
    »óº¯µ¿(ßÓܨÔÑ)
  • preinductive phase
    ÀüÀ¯µµ±â(îñë¯ÓôÑ¢)
  • productive phase
    »ý»ê±â(ßæß§Ñ¢)
  • reduction phase
    ȯ¿ø±â(ü½êªÑ¢)
  • regeneration phase
    Àç»ý±â(î¢ßæÑ¢)
  • reversed phase chromatography
    ¿ª»ó(æ½ßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • solid phase synthesis
    °í»óÇÕ¼º(ͳßÒùêà÷)
  • stationary phase
    "Á¤Áö»ó(ïÎò­ßÓ), Á¤Áö±â(ïÎò­Ñ¢)"
  • transient phase
    °úµµ»ó(ΦԤßÒ)
  • vapor phase chromatography
    Áõ±â»ó(ñúѨßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ARP absolute refractory period; American Registry of Pathologists; anticipated recovery path; apolipopro...
ASPS advanced sleep phase syndrome
CPIR cephalic-phase insulin release
CYCLOPS cyclically ordered phase sequence
DLP delipidized serum protein; direct linear plotting; dislocation of patella; distolinguopulpal; dyshar...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MSPD Matrix Solid-Phase Dispersion
NP Normal-phase
PC Phase Contrast
PCM Phase contrast microscopy
PRC Phase response curve
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • phase II treatment
    Á¦2´Ü°è Ä¡·á
  • phase mismapping
    À§»ó ¿ÀÁöµµ ÀÛ¼º
  • phase of meditation
    Àẹ ±â°£
  • phase shift
    À§»ó º¯À§
  • phase shift effect
    À§»ó º¯À§ È¿°ú
  • phase wrap
    À§»ó Æ÷Àå
  • phase wraparound artifact
    À§»ó Æ÷Àå Àΰø¹°
  • portal phase
    ¹®¸Æ±â
  • preeruptive phase
    ¸ÍÃâÀü ´Ü°è
  • prefunctional eruptive phase
    ±â´ÉÀü ¸ÍÃ⠴ܰè
  • premenstrual :

    premenstrual phase

    ¿ù°æ Àü±â
    ¿ù°æÀÌ °³½ÃÇÏ´Â Á÷Àü ½Ã±â.
  • prodromal vasoconstriction phase
    Àü±¸¼º Ç÷°ü ¼öÃà±â
  • proliferation phase
    Áõ½Ä±â
  • respiratory ordered phase encoding
    È£Èí ¼øÀ§ »ó ºÎȣȭ
  • rising phase
    »ó½Â±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
anal phase In psychoanalytic personality theory, the stage of psychosexual development, occurring when a child is between 1 and 3 years, during which activities, interests, and concerns are centreed around the anal zone.
(05 Mar 2000)
aqueous phase The water portion of a system consisting of two liquid phase's, one mainly water, the other a liquid immiscible with water (e.g., benzene, ether).
(05 Mar 2000)
blast phase Refers to advanced chronic myelogenous leukaemia. In this phase, the number of immature, abnormal white blood cells in the bone marrow and blood is extremely high. Also called blast crisis.
(12 Dec 1998)
g0 phase Phase of the cell cycle where cells exist in a quiescent state. These cells have unduplicated DNA, degraded RNA and protein, and low enzyme activity. The ability to switch between g0 and g1 (and vice versa) determines the post-embryonic cell proliferation rate and is defectively controlled in neoplastic cells.
(12 Dec 1998)
g1 phase <cell biology, molecular biology> The period during interphase in the cell cycle between mitosis and the S phase (when DNA is replicated).
Also known as the decision period of the cell, because the cell decides to divide when it enters the s phase. The G stands for gap.
(09 Oct 1997)
g2 phase <cell biology, molecular biology> The period during interphase in the cell cycle between the S phase (when DNA is replicated) and mitosis (when the nucleus, then cell, divides).
at this time, the cell checks the accuracy of DNA replication and prepares for mitosis. The G stands for gap.
(09 Oct 1997)
radial growth phase The early pattern of growth of cutaneous malignant melanoma, in which tumour cells spread laterally in the epidermis.
(05 Mar 2000)
Gap1 phase The period of the cell cycle after cell division when there is synthesis of RNA and protein; it may last for a few hours in rapidly growing tissue or a lifetime in non-renewing cells such as nerve cells.
Synonym: Gap1 phase, postmitotic phase.
(05 Mar 2000)
Gap2 phase The period in the cell cycle when synthesis of DNA is completed but before mitosis begins.
Synonym: Gap2 phase, premitotic phase.
(05 Mar 2000)
genital phase In psychoanalytic personality theory, the final stage of psychosexual development, occurring during puberty, in which the individual's psychosexual development is so organised that sexual gratification can be achieved from genital-to-genital contact and the capacity exists for a mature affectionate relationship with an individual of the opposite sex.
See: phallic phase.
(05 Mar 2000)
vertical growth phase Spread of melanoma cells from the epidermis into the dermis and later the subcutis, from which site metastasis may take place.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á